Brian M Maas

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 5

Top Topics

Coronavirus Disease

Placebo Controlled

Top Venues

Clinical and translational science

CPT: pharmacometrics & systems pharmacology

Clinical pharmacology and therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Brian M Maas, Julie M Strizki, Randy R Miller, Sushma Kumar, Michelle Brown, Matthew G Johnson, Mickie Cheng, Carisa De Anda, Matthew L Rizk, Julie A Stone
Molnupiravir: Mechanism of action, clinical, and translational science. Clinical and translational science 17 (2) (2024)
Brian M Maas, Julie M Strizki, Randy R Miller, Sushma Kumar, Michelle Brown, Matthew G Johnson, Mickie Cheng, Carisa De Anda, Matthew L Rizk, Julie A Stone
Molnupiravir: Mechanism of action, clinical, and translational science. Clinical and translational science 17 (2) (2024)
Akshita Chawla, Ruthie Birger, Hong Wan, Youfang Cao, Brian M Maas, Amanda Paschke, Carisa De Anda, Matthew L Rizk, Julie A Stone
Factors Influencing COVID-19 Risk: Insights from Molnupiravir Exposure-Response Modeling of Clinical Outcomes. Clinical pharmacology and therapeutics (2023)
Sébastien Bihorel, Youfang Cao, Akshita Chawla, Ruthie B Birger, Brian M Maas, Wei Gao, Stefan Roepcke, Susanne Sardella, Rebecca Humphrey, Sindhuri Kondragunta, Bhuvana Jayaraman, Monika Martinho, Wendy Painter, George Painter, Wayne Holman, Carisa De Anda, Michelle L Brown, Matthew G Johnson, Amanda Paschke, Matthew L Rizk, Julie A Stone
Population pharmacokinetics of molnupiravir in adults with COVID-19: Lack of clinically important exposure variation across individuals. CPT: pharmacometrics & systems pharmacology (2023)
Brian M Maas, Yanguang Cao
A minimal physiologically based pharmacokinetic model to investigate FcRn-mediated monoclonal antibody salvage: Effects of Kon, Koff, endosome trafficking, and animal species. mAbs 10 (8) (2018)